These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9021256)

  • 1. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis.
    Rothstein JD
    Clin Neurosci; 1995-1996; 3(6):348-59. PubMed ID: 9021256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased internalisation and degradation of GLT-1 glial glutamate transporter in a cell model for familial amyotrophic lateral sclerosis (ALS).
    Vanoni C; Massari S; Losa M; Carrega P; Perego C; Conforti L; Pietrini G
    J Cell Sci; 2004 Oct; 117(Pt 22):5417-26. PubMed ID: 15466883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.
    Rothstein JD
    Adv Neurol; 1995; 68():7-20; discussion 21-7. PubMed ID: 8787245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis.
    Heath PR; Shaw PJ
    Muscle Nerve; 2002 Oct; 26(4):438-58. PubMed ID: 12362409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic mechanisms in amyotrophic lateral sclerosis.
    Sandyk R
    Int J Neurosci; 2006 Jul; 116(7):775-826. PubMed ID: 16861147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic elevation of extracellular glutamate due to transport blockade is innocuous for spinal motoneurons in vivo.
    Tovar-Y-Romo LB; Santa-Cruz LD; Zepeda A; Tapia R
    Neurochem Int; 2009; 54(3-4):186-91. PubMed ID: 19100799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late appearance of glutamate transporter defects in a murine model of ALS-parkinsonism dementia complex.
    Wilson JM; Shaw CA
    Neurochem Int; 2007 Jun; 50(7-8):1067-77. PubMed ID: 17095122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered in-vitro and in-vivo expression of glial glutamate transporter-1 following exposure to cerebrospinal fluid of amyotrophic lateral sclerosis patients.
    Shobha K; Vijayalakshmi K; Alladi PA; Nalini A; Sathyaprabha TN; Raju TR
    J Neurol Sci; 2007 Mar; 254(1-2):9-16. PubMed ID: 17254611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.
    Rothstein JD; Van Kammen M; Levey AI; Martin LJ; Kuncl RW
    Ann Neurol; 1995 Jul; 38(1):73-84. PubMed ID: 7611729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.
    Rothstein JD; Martin LJ; Kuncl RW
    N Engl J Med; 1992 May; 326(22):1464-8. PubMed ID: 1349424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The causes and mechanism of selective motor neuron death in amyotrophic lateral sclerosis].
    Van den Bosch L
    Verh K Acad Geneeskd Belg; 2006; 68(4):249-69. PubMed ID: 17214440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant control of motoneuronal excitability in amyotrophic lateral sclerosis: excitatory glutamate/D-serine vs. inhibitory glycine/gamma-aminobutanoic acid (GABA).
    Sasabe J; Aiso S
    Chem Biodivers; 2010 Jun; 7(6):1479-90. PubMed ID: 20564566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective up-regulation of the glial Na+-dependent glutamate transporter GLT1 by a neuroimmunophilin ligand results in neuroprotection.
    Ganel R; Ho T; Maragakis NJ; Jackson M; Steiner JP; Rothstein JD
    Neurobiol Dis; 2006 Mar; 21(3):556-67. PubMed ID: 16274998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of AMPA receptors and VEGF in ALS.
    Van Damme P
    Verh K Acad Geneeskd Belg; 2009; 71(4):241-50. PubMed ID: 20084835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors.
    Whitehouse PJ; Wamsley JK; Zarbin MA; Price DL; Tourtellotte WW; Kuhar MJ
    Ann Neurol; 1983 Jul; 14(1):8-16. PubMed ID: 6137185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential abundance of glutamate transporter subtypes in amyotrophic lateral sclerosis (ALS)-vulnerable versus ALS-resistant brain stem motor cell groups.
    Medina L; Figueredo-Cardenas G; Rothstein JD; Reiner A
    Exp Neurol; 1996 Dec; 142(2):287-95. PubMed ID: 8934560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis.
    Plaitakis A
    Ann Neurol; 1990 Jul; 28(1):3-8. PubMed ID: 1973889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excitotoxicity and amyotrophic lateral sclerosis.
    Van Damme P; Dewil M; Robberecht W; Van Den Bosch L
    Neurodegener Dis; 2005; 2(3-4):147-59. PubMed ID: 16909020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neural degeneration and the transport of neurotransmitters.
    Edwards RH
    Ann Neurol; 1993 Nov; 34(5):638-45. PubMed ID: 7902065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the GLT-1 subtype of glutamate transporter in glutamate homeostasis: the GLT-1-preferring inhibitor WAY-855 produces marginal neurotoxicity in the rat hippocampus.
    Selkirk JV; Nottebaum LM; Vana AM; Verge GM; Mackay KB; Stiefel TH; Naeve GS; Pomeroy JE; Petroski RE; Moyer J; Dunlop J; Foster AC
    Eur J Neurosci; 2005 Jun; 21(12):3217-28. PubMed ID: 16026460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.